These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 35925567)

  • 1. Plasma Levels of Vascular Endothelial Growth Factor After Low-Dose Bevacizumab Treatment for Retinopathy of Prematurity Study-More Questions Than Answers.
    Raghuveer TS; Binder S
    JAMA Ophthalmol; 2022 Sep; 140(9):910-911. PubMed ID: 35925567
    [No Abstract]   [Full Text] [Related]  

  • 2. Plasma Levels of Vascular Endothelial Growth Factor After Low-Dose Bevacizumab Treatment for Retinopathy of Prematurity Study-More Questions Than Answers?-Reply.
    Hartnett ME; Wallace DK
    JAMA Ophthalmol; 2022 Sep; 140(9):911-912. PubMed ID: 35925587
    [No Abstract]   [Full Text] [Related]  

  • 3. Fundus Pigmentation in the Diagnosis and Treatment of Retinopathy of Prematurity.
    Fan KC; Read SP; Patel NA; Vanner EA; Al-Khersan H; Laura DM; Pakravan P; Negron CI; Berrocal AM
    Ophthalmology; 2021 Aug; 128(8):1242-1244. PubMed ID: 33383092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PLASMA CONCENTRATIONS OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN RETINOPATHY OF PREMATURITY AFTER INTRAVITREAL BEVACIZUMAB INJECTION.
    Hong YR; Kim YH; Kim SY; Nam GY; Cheon HJ; Lee SJ
    Retina; 2015 Sep; 35(9):1772-7. PubMed ID: 25829347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravitreal bevacizumab for retinopathy of prematurity: Considerations for informed consent.
    Mireskandari K; Collins ME; Tehrani N
    Can J Ophthalmol; 2015 Dec; 50(6):409-12. PubMed ID: 26651298
    [No Abstract]   [Full Text] [Related]  

  • 6. A lower dose of intravitreal bevacizumab effectively treats retinopathy of prematurity.
    Khodabande A; Niyousha MR; Roohipoor R
    J AAPOS; 2016 Dec; 20(6):490-492. PubMed ID: 27794470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Timing of laser following intravitreal anti-vascular endothelial growth factor injections for aggressive posterior zone 1 retinopathy of prematurity.
    Vinekar A
    Indian J Ophthalmol; 2021 Aug; 69(8):1988-1989. PubMed ID: 34304161
    [No Abstract]   [Full Text] [Related]  

  • 8. Anti-vascular Endothelial Growth Factor Treatment of Retinopathy of Prematurity: Efficacy, Safety, and Anatomical Outcomes.
    Kang HG; Choi EY; Byeon SH; Kim SS; Koh HJ; Lee SC; Kim M
    Korean J Ophthalmol; 2018 Dec; 32(6):451-458. PubMed ID: 30549468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retinopathy of Prematurity: Intravitreal injections of bevacizumab: timing, technique, and outcomes.
    Mintz-Hittner HA
    J AAPOS; 2016 Dec; 20(6):478-480. PubMed ID: 27816750
    [No Abstract]   [Full Text] [Related]  

  • 10. Quantitative comparison of blood vessel changes after treatment of retinopathy of prematurity with laser versus bevacizumab.
    Wang W; Hong GJ; Stinnett SS; Freedman SF; Wallace DK; Prakalapakorn SG
    J AAPOS; 2022 Dec; 26(6):323-326. PubMed ID: 36152755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Very Late Reactivation of Retinopathy of Prematurity After Monotherapy With Intravitreal Bevacizumab.
    Snyder LL; Garcia-Gonzalez JM; Shapiro MJ; Blair MP
    Ophthalmic Surg Lasers Imaging Retina; 2016 Mar; 47(3):280-3. PubMed ID: 26985803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal bevacizumab following laser therapy for severe retinopathy of prematurity.
    Erol N; Gürsoy H; Sahin A; Basmak H
    J Pediatr Ophthalmol Strabismus; 2010 Aug; 47 Online():e1-4. PubMed ID: 21158371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ultra-low dose of intravitreal bevacizumab in the treatment of retinopathy of prematurity.
    Connor AJ; Papastavrou VT; Hillier RJ; Shafiq A
    J Pediatr Ophthalmol Strabismus; 2015 Apr; 52 Online():e20-1. PubMed ID: 25942065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity.
    Karkhaneh R; Khodabande A; Riazi-Eafahani M; Roohipoor R; Ghassemi F; Imani M; Dastjani Farahani A; Ebrahimi Adib N; Torabi H
    Acta Ophthalmol; 2016 Sep; 94(6):e417-20. PubMed ID: 27009449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab for retinopathy of prematurity.
    Gilbert CE; Zin A; Darlow B
    N Engl J Med; 2011 Jun; 364(24):2359-60; author reply 2361-2. PubMed ID: 21675898
    [No Abstract]   [Full Text] [Related]  

  • 16. OUTCOMES OF NONCONFLUENT DIODE LASER PANRETINAL PHOTOCOAGULATION FOR AGGRESSIVE POSTERIOR RETINOPATHY OF PREMATURITY AFTER INTRAVITREAL BEVACIZUMAB.
    Mammo DA; Rubino SM; Quiram PA
    Retina; 2021 Apr; 41(4):706-710. PubMed ID: 32796444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab for retinopathy of prematurity and neurodevelopment.
    Binenbaum G
    J AAPOS; 2023 Feb; 27(1):1-2. PubMed ID: 36623638
    [No Abstract]   [Full Text] [Related]  

  • 18. Bilateral effect of unilateral bevacizumab injection in retinopathy of prematurity.
    Karaca C; Oner AO; Mirza E; Polat OA; Sahiner M
    JAMA Ophthalmol; 2013 Aug; 131(8):1099-101. PubMed ID: 23744183
    [No Abstract]   [Full Text] [Related]  

  • 19. [Neurodevelopment in patients with retinopathy of prematurity treated with intravitreal bevacizumab. Case series].
    Martínez-García SM; Hernández-Da Mota SE; Rubio-Rangel A; Rojas-Flores I; Vieyra-López ME; Martínez-Castellanos MA; Zavala-Martínez MT; Gómez García A
    Cir Cir; 2017; 85(6):478-484. PubMed ID: 28110900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of Plasma Cytokine Profile Changes in Bevacizumab-Treated Retinopathy of Prematurity Infants.
    Kong L; Demny AB; Sajjad A; Bhatt AR; Devaraj S
    Invest Ophthalmol Vis Sci; 2016 Apr; 57(4):1649-54. PubMed ID: 27054517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.